linjc16/ctgov huggingface dataset:
The Evaluation of the Ultrasound-guided Clinical Procedure Simulation Curriculum

Study Overview
=================
Brief Summary
-----------------
Ultrasound is a non-radiated diagnostic tool that can be performed at the bedside in emergency departments and critical care settings. Traditionally, junior residents learn from patients by performing sonography on them. However, patient rights, patient safety, and medical quality are raising concerns. How to enable junior doctors to be effectively familiar with ultrasound operations and to effectively integrate them into daily practice has become a major challenge in medical education. Also, the ultrasound-guided clinical procedure is included in the ultrasound core applications in the American College of Emergency Physicians statements. This aim of this study is to establish an ultrasound-guided simulation curriculum and to evaluate the efficacy. The subjects of the study are junior doctors who are interested in clinical procedures in the emergency department or other relevant medical departments, and it is estimated that 200 people will be enrolled.

Official Title
-----------------
The Evaluation of the Ultrasound-guided Clinical Procedure Simulation Curriculum

Conditions
-----------------
Ultrasound Performance

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: participants attended the curriculum. Exclusion Criteria: not attended the curriculum

Ages Eligible for Study
-----------------
Minimum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ultrasound-guided clinical procedure | thoracocentesis, abdominal tapping, vasculizastion | 3 months |
Expectations, Satisfaction and Quality of Life in Total Hip Arthroplasty

Study Overview
=================
Brief Summary
-----------------
The goals of this study are to identify predictors of improvement in quality of life and satisfaction with total hip arthroplasty three to five years after surgery.

Detailed Description
-----------------
The goals of this study are to identify predictors of improvement in quality of life and satisfaction with total hip arthroplasty three to five years after surgery. Predictors that will be considered are variables that were obtained prospectively and systematically at the time of surgery, including demographic characteristics, functional status, expectations, perioperative complications, and comorbidity. At the follow-up functional status and patient satisfaction will be measured, as well as fulfillment of expectations and predispositional factors.

Official Title
-----------------
Expectations, Satisfaction and Quality of Life in Total Hip Arthroplasty

Conditions
-----------------
Hip Osteoarthritis, Arthroplasty, Replacement, Hip

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients will be eligible for this study if they are part of an assembled cohort of patients who underwent primary unilateral or bilateral total hip arthroplasty in 1998-2000 at the Hospital for Special Surgery. Exclusion Criteria: Patients will be excluded if they are unable to be interviewed, refuse to participate, or are deceased.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fulfillment of expectations |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Satisfaction with THA |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
total hip arthroplasty, expectations, satisfaction, quality of life
Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia

Study Overview
=================
Brief Summary
-----------------
Iron overload is well study in Thalassemia patients and it's not only related to blood transfusions, since intestinal iron absorption is also increased in those patients. Sickle cell patients didn't developed significant clinical symptoms and signs of iron overload in spite frequent transfusions. The purpose of this study is to assess the iron overload in Sickle cell anemia and Sickle cell Thalassemia patients using clinical parameters and laboratory studies including Non Transferrin Binding Iron, Labile Iron and Hepcidin, in order to determine the cardiac and liver iron.

Official Title
-----------------
Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia - An Observational and Laboratory Study

Conditions
-----------------
Sickle Cell Anemia, Sickle Cell Thalassemia

Intervention / Treatment
-----------------
* Other: Laboratory analyses of iron overload


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All the patients with Sickle Cell Anemia and Sickle Cell Thalassemia that are treated and followed up at the Pediatric Hematology Unit.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Patients suffering from Sickle cell disease | Other: Laboratory analyses of iron overload<br>* Summary of clinical status related to iron overload and laboratory analysis of Iron overload including Total serum Iron, Transferrin, Ferritin and Non transferrin Binding Iron and Labile Plasma Iron<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sickle Cell Anemia, Sickle Cell Thalassemia, Iron overload, Non transferrin binding iron, Hepcidin
Post-operative Sore Throat as Determined by Endotracheal Tube Inflation Technique

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test whether the incidence of sore throat and other tracheal co-morbidities such as dysphagia and hoarseness can be lessened by use of a cuff manometer at the beginning of surgery to inflate to the proper pressure compared to the standard technique. The investigators hypothesis is that inflation of the endotracheal balloon using a cuff manometer immediately after intubation will reduce the incidence of sore throat and other tracheal co-morbidities.

Official Title
-----------------
Post-operative Sore Throat as Determines by Endotracheal Tube Inflation Technique

Conditions
-----------------
Post Operative Sore Throat, Dysphagia, Hoarseness

Intervention / Treatment
-----------------
* Device: cuff manometer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Scheduled for general anesthesia requiring endotracheal intubation with planned duration of at least 2 hours ASA I-3 Exclusion Criteria: Planned prolonged intubation Planned postoperative ICU admission Non English speaking Mentally impaired Existing tracheal stoma Nasogastric tube in place preoperative Thyroid / intra-oral surgery Previous general anesthesia within the last 2 weeks Use of steroids within one week before surgery (IV,inhaled, oral)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: intervention<br>Endotracheal tube will be adjusted to 22-26 cm H20 pressure immediately post intubation using a cuff manometer | Device: cuff manometer<br>* endotracheal tube cuff will be inflated to 22-26 cm H20 using cuff manometer<br>|
| No Intervention: control<br>endotracheal tube cuff will be inflated using standard technique | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Tracheopharyngeal Symptoms |  | within 2 hours after extubation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sore throat, dysphagia, hoarseness, post operative, endotracheal intubation
Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty

Study Overview
=================
Brief Summary
-----------------
To evaluate the safety and effectiveness of Trabecular Micro-Bypass stents (two stents per study eye) vs. laser trabeculoplasty, in subjects with open angle glaucoma

Conditions
-----------------
Primary Open-Angle Glaucoma

Intervention / Treatment
-----------------
* Device: Stents
* Procedure: Laser
* Device: Laser Trabeculoplasty


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Open angle Glaucoma Exclusion Criteria: Active corneal inflammation or edema Choroidal detachment, effusion, choroiditis

Ages Eligible for Study
-----------------
Minimum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Surgical<br>Implantation of two Trabecular Meshwork stents into the study eye | Device: Stents<br>* Two Trabecular meshwork Micro-Bypass stents into the study eye<br>|
| Active Comparator: Laser<br>Laser Trabeculoplasty | Procedure: Laser<br>* Laser Trabeculoplasty<br>Device: Laser Trabeculoplasty<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IOP reduction |  | up to 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| % IOP reduction |  | up to 24 months |
The Effect of Mid-urethral Sling on the Urethral Dynamic Shape and Motion

Study Overview
=================
Brief Summary
-----------------
The purpose of this prospective cohort study is to investigate the effect of sling on urethral dynamic shape and motion using static and dynamic pelvic floor ultrasound and additionally compare the findings among women with successful vs failed surgical outcome.

Detailed Description
-----------------
This study is designed as a prospective cohort study. Our hypothesis is that mid-urethral sling provides backstop for excessive swing motion of distal urethra and helps with urethral compression along its luminal axis. Aim 1: Investigate the effect of mid-urethral sling on the urethral shape at rest and maximum Valsalva, in other words dynamic urethral shape. Aim 2: Compare the effect of mid-urethral sling on urethral dynamic shape in women with successful surgical outcome (absence of stress urinary incontinence at 3 and 12 months after the surgery) and women with surgical failure (presence of stress urinary incontinence at 3 and 12 months after the surgery).

Official Title
-----------------
The Effect of Mid-urethral Sling on the Urethral Dynamic Shape and Motion

Conditions
-----------------
Stress Urinary Incontinence

Intervention / Treatment
-----------------
* Procedure: Mid-urethral sling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: stress urinary incontinence interested in treatment with mid-urethral sling able to consent in english and come to post-operative and research visits Exclusion Criteria: contraindication to mid-urethral sling detrusor overactivity > 40cm H2O post-void residual > 150mL Maximum urethral closure pressure < 40 cm H2O

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Mid-urethral sling|Treatment of stress urinary incontinence with retropubic mid-urethral sling|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Urethral Shape at 3 months | Urethral shape measured by ultrasound | 3 months | 
| Urethral Motion at 3 months | Urethral motion measured by ultrasound | 3 months | 
| Urethral Shape at 12 months | Urethral shape measured by ultrasound | 12 months | 
| Urethral Motion at 12 months | Urethral motion measured by ultrasound | 12 months |
Evaluation of Phlebotomy as a Treatment for Non-alcoholic Fatty Liver Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the use of phlebotomy (blood taking)as a treatment for patients with non-alcoholic fatty liver disease.

Detailed Description
-----------------
In this study phlebotomy will be evaluated as a therapy for non-alcoholic fatty liver disease (NAFLD), a common and important cause of liver disease. Phlebotomy has been used for many years in the treatment of disorders of iron overload such as hemochromatosis, where it is well tolerated and improves symptoms and survival. There is some evidence that it is also effective in treating NAFLD. However, previous studies have not evaluated whether phlebotomy improves liver biopsy findings. We will measure the severity disease in NAFLD patients prior to phlebotomy therapy and again at the end of treatment. This will allow us to accurately determine the benefit of this therapy in these patients.

Official Title
-----------------
Evaluation of Phlebotomy as a Treatment for Non-alcoholic Fatty Liver Disease

Conditions
-----------------
Non-alcoholic Fatty Liver Disease

Intervention / Treatment
-----------------
* Procedure: Phlebotomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients 18y or older Diagnosis of Non-alcoholic Fatty Liver Disease Exclusion Criteria: Unable or unwilling to provide informed consent Alcohol consumption of >10g/day for women and >20g/day for men

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: treatment<br>Iron depletion via phlebotomy | Procedure: Phlebotomy<br>* Phlebotomy involves the removal of blood (approximately 500mL) each week until body iron levels reach the low-normal level<br>* Other names: Venesection;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Severity of liver disease |  | 6 months after final treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Severity of metabolic disease |  | 6 months after final treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non-alcoholic fatty liver disease, liver fibrosis, metabolic syndrome, iron overload, phlebotomy
Evaluation of GvHD Damage on Medullary Mesenchymal Stem Cells

Study Overview
=================
Brief Summary
-----------------
Spontaneous, multicenter, prospective, non-pharmacological study. At the diagnosis of acute or chronic GvHD after HSCT, bone marrow cells will be analysed for MSC content and properties. Bone marrow aspirate will be performed according to usual clinical practise

Official Title
-----------------
Prospective Multicenter Study for the Evaluation of GvHD Damage on Medullary Mesenchymal Stem Cells - GvHD Damage on MSCs

Conditions
-----------------
Graft Vs Host Disease

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients (children and adults) developing acute or chronic GvHD after HSCT. Age 6 months- month-99 years, Landsky-Karnofsky> 70%, Acute or chronic GvHD needing further immunosuppressive treatment. Exclusion Criteria: Anything not included in the inclusion criteria.

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: no intervention|no intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of damage generated by acute or chronic GvHD on the MSCs after HSCT |  | Through study completion, an average of 1 year |
Cord Blood 25(oh)-Vitamin D Level in Preterm Infants and Associated Morbidities

Study Overview
=================
Brief Summary
-----------------
Experimental and observational studies have shown that vitamin D deficiency may be associated with an increased risk for non-bone diseases and/or abnormal development for the other systems of fetus. The aim of this study is to determine the relationship between cord blood 25-hydroxyvitamin D (25 (OH) D) concentrations and the subsequent risk of morbidities including RDS, PDA, NEC, BPD AND ROP in preterm infants.

Detailed Description
-----------------
It was shown that vitamin D play important role in the pathogenesis of long term morbidities of newborn. Experimental and observational studies have shown that vitamin D deficiency may be associated with an increased risk for non-bone diseases and/or abnormal development for the other systems of fetus. The aim of this study is to determine the relationship between cord blood 25-hydroxyvitamin D (25 (OH) D) concentrations and the subsequent risk of morbidities including RDS, PDA, NEC, BPD AND ROP in preterm infants.

Official Title
-----------------
Is Higher Cord Blood 25(Oh)-Vitamin D Level Preventive For Any Morbidity Including Rds, Pda, Nec, Bpd And Rop In Preterm Infants

Conditions
-----------------
Respiratory Distress Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: infants <32 weeks of gestational age Exclusion Criteria: infants with major congenital abnormality infants >32 weeks of gestational age

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 5 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Low vitamin D level<br>The premature infants with low cord blood vitamin D level | |
| Normal Vitamin D<br>The premature infants with normal vitamin D level | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Respiratory Distress Syndrome | The association of vitamin D level with respiratory distress syndrome | three days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sepsis | Association of vitamin D level with sepsis | four weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
vitamin D, Respiratory distress syndrome, sepsis, preterm
Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation

Study Overview
=================
Brief Summary
-----------------
Investigate changes in optical coherence tomography angiography of the optic nerve and macula following topical instillation of commercial preparations of netarsudil 0.02% ophthalmic solution.

Official Title
-----------------
Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation

Conditions
-----------------
Glaucoma, Open-Angle

Intervention / Treatment
-----------------
* Drug: Netarsudil Ophthalmic


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal ocular health Exclusion Criteria: Females who are or may be pregnant or who are nursing Uncontrolled hypertension Allergy to netarsudil or latanoprost

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Netarsudil alone<br>Topical application of netarsudil 0.02% | Drug: Netarsudil Ophthalmic<br>* Topical instillation of commercial preparations of netarsudil 0.02% ophthalmic solution (Rhopressa and Roclatan)<br>* Other names: Latanoprost Ophthalmic;|
| Active Comparator: Netarsudil plus latanoprost<br>Topical application of netarsudil 0.02% with latanoprost 0.005% | Drug: Netarsudil Ophthalmic<br>* Topical instillation of commercial preparations of netarsudil 0.02% ophthalmic solution (Rhopressa and Roclatan)<br>* Other names: Latanoprost Ophthalmic;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peripapillary capillary perfusion density | Mean change in peripapillary capillary perfusion as assessed using optical coherence tomography angiography | 90 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Macular capillary perfusion density | Mean change in macular capillary perfusion as assessed using optical coherence tomography angiography | 90 minutes |